Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

DISEASE CHARACTERISTICS:

Histologically confirmed stage III or IV ovarian epithelial cancer or primary peritoneal cavity cancer meeting 1 of the following criteria:

Progressive* or persistent* disease during or after primary chemotherapy
Recurrent disease < 6 months after completion of primary therapy that had resulted in a complete response
Persistent* or recurrent disease after second-line or additional therapies NOTE: *Progression or persistence can be based on serological (CA 125 > 100 U/mL OR 2 times baseline), radiographic (measurable or evaluable disease), or second-look surgical findings
Tumor expressing NY-ESO-1 determined by IHC or RT-PCR
HLA type expressing DPB*0401, DPB1*0201, DRB1*07
No CNS metastases

PATIENT CHARACTERISTICS:

Age

18 to 75

Performance status

Karnofsky 70-100%

Life expectancy

More than 16 weeks

Hematopoietic

Not specified

Hepatic

Not specified

Renal

Creatinine ≤ 2.0 mg/dL

Cardiovascular

No congestive heart failure*
No clinically significant hypotension*
No symptoms of coronary artery disease*
No cardiac arrhythmias on EKG requiring drug therapy*
No history of cardiovascular disease*
No other significant cardiovascular abnormalities* NOTE: *Patients with any of the above undergo a stress test and/or echocardiography before being determined ineligible for study participation

Pulmonary

FEV_1 ≥ 60% of predicted*
DLCO ≥ 55%* NOTE: *Patients with clinically significant pulmonary dysfunction only

Other

Not pregnant or nursing
Fertile patients must use effective contraception
HIV negative
No active infection
No oral temperature > 38.2°C within the past 72 hours
No systemic infection requiring chronic maintenance or suppressive therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

No other concurrent immunotherapy (e.g., interleukins, interferons, vaccines, intravenous immunoglobulin, or expanded polyclonal tumor-infiltrating lymphocytes or lymphokine-activated killer cell therapy)

Chemotherapy

See Disease Characteristics
At least 3 weeks since prior standard or experimental chemotherapy

Endocrine therapy

No concurrent systemic corticosteroids except for treatment-related toxicity

Radiotherapy

At least 3 weeks since prior radiotherapy

Surgery

See Disease Characteristics

Other

At least 3 weeks since prior immunosuppressive therapy
More than 3 weeks since prior investigational drugs and recovered
No other concurrent investigational agents
No concurrent pentoxifylline